cJc-1295 With DAc

What is CJC-1295 With DAC?

CJC-1295 with DAC is a synthetic peptide designed for long-acting growth hormone release. The key is the DAC.

• CJC-1295: This part is an analog of Growth Hormone-Releasing Hormone (GHRH), similar to the “no DAC” version.

• DAC (Drug Affinity Complex): This is a chemical moiety that binds the peptide tightly to albumin, a common protein in the bloodstream.

This binding to albumin is the game-changer. It prevents the peptide from being filtered out by the kidneys, allowing it to circulate in the blood for an extended period—over a week from a single injection.

Mechanism of Action: Continuous Stimulation

Unlike the pulsatile, short-lived release caused by CJC-1295 without DAC, the version with DAC creates a sustained, non-pulsatile elevation of Growth Hormone (GH) and Insulin-like Growth Factor-1 (IGF-1).

• Natural GH Release: Your body naturally releases GH in sharp, discrete pulses, mainly during deep sleep and after exercise. This pulsatility is crucial for its proper effects and safety.

• CJC-1295 with DAC’s Action: After injection, it continuously stimulates the pituitary gland. There is no “off” switch. This leads to a constant, elevated baseline of GH, which the liver then converts into a consistently high level of IGF-1.

Clinical Research and Results

CJC-1295 with DAC was initially studied for treating Growth Hormone Deficiency (GHD). Key findings from early clinical trials:

• Prolonged Action: A single injection increased mean plasma GH levels by 2-10 times for over 6 days.

• Increased IGF-1: It raised IGF-1 levels for over 9-11 days.

• Dosing: The effects were dose-dependent, and injections were given as infrequently as once or twice a week.

While the results demonstrated powerful biological activity, the continuous, non-physiological release profile raised significant safety concerns, which ultimately limited its clinical development.

Use in Bodybuilding and Performance Enhancement

In the performance-enhancing world, CJC-1295 with DAC is used for its “set-and-forget” convenience and potent anabolic effects.

• The Appeal: Users are attracted to the idea of needing only one or two injections per week to maintain highly elevated anabolic hormone levels (IGF-1).

• The Goal: To promote continuous muscle growth, fat loss, and recovery.

Side Effects and Significant Risks

This is the most critical section. The side effect profile of CJC-1295 with DAC is far more concerning than that of the “no DAC” version due to its continuous action.

1. Negative Feedback and Desensitization: Constant stimulation of the pituitary gland can cause it to become desensitized to GHRH. This may lead to a shutdown of natural GH production, potentially causing a dependency or a crash after discontinuing use.

2. Acromegaly-like Symptoms: This is the single biggest risk. Acromegaly is a disease caused by a pituitary tumor that leads to constant, high GH/IGF-1. Symptoms can include:

   • Joint Pain and Swelling

   • Carpal Tunnel Syndrome

   • Coarse, Thickening of the Skin

   • Enlargement of the Hands, Feet, and Facial Bones (bossing)

   • Organ Growth (e.g., enlarged heart)

3. Severe Insulin Resistance: Constant high GH directly antagonizes insulin, dramatically increasing the risk of developing type 2 diabetes.

4. Water Retention (Edema): Can be severe and uncomfortable.

5. Hypertension (High Blood Pressure): Often linked to water retention and insulin resistance.

Direct Comparison: CJC-1295 WITH DAC vs. WITHOUT DAC

Key Takeaways

• CJC-1295 with DAC is a long-acting growth hormone releaser that creates a continuous, non-physiological elevation of GH and IGF-1.

• It is philosophically and mechanistically opposite to the “no DAC” version, which aims to mimic natural pulses.

• The convenience of infrequent dosing comes with a dramatically increased risk profile, including the potential for acromegaly-like symptoms and severe metabolic dysfunction.

• It is not synergistic with GHRPs like Ipamorelin and is generally considered an outdated and higher-risk choice compared to modern pulsatile secretagogue stacks.

• It is a research chemical with halted clinical development and is not approved for human use.